Journal article · 2026 · Open access

Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand?

Yun Chen

Targetome, 2(1), 0 · Published 1 January 2026 · DOI 10.48130/targetome-0026-0004

Open PDFView at the publisherCite this paper

In brief

“Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand?” is a 2026 journal article by Yun Chen, published in Targetome. OpenAlex counts 1 citations as of 18 November 2026, which puts it in the top 9% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at Targetome.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
1.39
References
58
Authors
1

Abstract

A new study published inNature Neurosciencedemonstrated that Fc effector function is essential for amyloid aggregate clearance during lecanemab treatment, a recently FDA-approved therapy for Alzheimer's disease. These findings underscore the requirement for intact Fc-mediated activity to achieve therapeutic efficacy. In addition, single-cell RNA sequencing identified microglia transcriptomic changes that are unique to lecanemab treatment and extend beyond previously characterized microglial activation signatures. Together with a retrospective review of anti-amyloid antibody development and related mechanisms, this commentary provides important insights into new directions for the design of next-generation therapies for Alzheimer's disease.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Chen, Y. (2026). Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand? Targetome, 2(1), 0. https://doi.org/10.48130/targetome-0026-0004

MLA 9

Chen, Yun. “Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand?” Targetome, vol. 2, no. 1, 2026, p. 0. https://doi.org/10.48130/targetome-0026-0004.

Chicago

Chen, Yun. 2026. “Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand?” Targetome 2 (1): 0. https://doi.org/10.48130/targetome-0026-0004.

Harvard

Chen, Y. (2026) ‘Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand?’, Targetome, 2(1), p. 0. doi:10.48130/targetome-0026-0004.

IEEE

Y. Chen, “Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand?,” Targetome, vol. 2, no. 1, p. 0, 2026, doi: 10.48130/targetome-0026-0004.

BibTeX

@article{chen2026anti,
  title     = {{Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand?}},
  author    = {Chen, Yun},
  journal   = {Targetome},
  year      = {2026},
  volume    = {2},
  number    = {1},
  pages     = {0},
  doi       = {10.48130/targetome-0026-0004},
  url       = {https://doi.org/10.48130/targetome-0026-0004}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • anti-amyloid antibodies
  • lecanemab
  • Fc effector functions
  • microglial activation
  • single-cell RNA sequencing

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Chen, Y. (2026). Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand? Targetome, 2(1), 0. https://doi.org/10.48130/targetome-0026-0004

How many times has this paper been cited?

1 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Targetome: sign in and open the PDF from this page.

Who wrote this paper?

Yun Chen.

What is the DOI of this paper?

10.48130/targetome-0026-0004, permanently at https://doi.org/10.48130/targetome-0026-0004. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.